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criteria, of which 3,152 (15.1%) underwent additional diagnostic imaging in the 6 
months post-index. White women were 1.12 times more likely to be recalled than 
African-American women (p< 0.001). Average costs per patient recalled were $838 
among white women and $804 among African-American women. Overall, 28.6% 
of costs were from additional imaging (diagnostic mammography and/or ultra-
sound), 39.2% were from guided biopsy procedures, and 24.4% from open biopsy. 
Recall-related office visits, MRI, fine needle aspiration, and ductogram accounted 
for < 5% of recall costs. Individual recall procedure rates were substantively simi-
lar between White and African-American recalled patients but African-American 
women had higher per-patient imaging costs and lower per-patient open biopsy 
costs. CONCLUSIONS: Improving breast cancer screening with a more accurate 
mammogram may significantly reduce Medicaid costs as approximately one-in-six 
women undergo additional diagnostic imaging following a screening mammogram 
with substantial associated costs. Recall rate and costs varied by race.
PHS48
Direct anD inDirect coStS to emPloyerS of recall following 
Screening mammograPHy among female emPloyeeS in tHe uS
Bonafede M.M.1, Miller J.D.1, Huang A.2, Troeger K.A.3, Fajardo L.4
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA, 
3Hologic, Inc., Marlborough, MA, USA, 4University of Iowa, Iowa City, IA, USA
OBJECTIVES: To describe the burden of recall following traditional screening mam-
mography from the perspective of US self-insured employers. METHODS: The 
Truven Health MarketScan Commercial and Health and Productivity Management 
Databases were used to identify female employees aged 40-65 years undergo-
ing screening mammography (index event) in 2010-2012 with at least 12 months 
pre- and 6 months post-index continuous enrollment; patients with a breast 
cancer diagnosis in the pre-index period were excluded. Recall was defined as 
receipt of diagnostic mammogram or ultrasound in the six months following the 
index screen. Employer cost per recall (2013 US$) was the sum of breast-related 
imagining procedures and associated diagnostic procedure costs in the 6 months 
post-index, excluding patient payments and breast cancer treatment costs. 
Absenteeism costs were calculated using a wage constant ($38/hour). RESULTS: 
Of the 339,912 patients who met the study criteria, 47,321 (13.4%) underwent 
additional diagnostic imaging within 6 months post-index with an average direct 
medical cost to employers of $1,279 per patient recalled. Nearly one-fourth (23.4%) 
of recall costs was attributable to additional imaging (diagnostic mammography 
or ultrasound), 40.0% was attributable to guided biopsy and 28.0% attributable to 
open biopsy. One-fifth (21.9%) of recalled patients had at least two days with recall-
related procedures while 4.2% had at least three recall event days. Absenteeism 
costs were $948 in the 30 days following recall among patients with absenteeism 
claims (67.2%), increasing to $4,472 over 6 months post-recall among patients with 
absenteeism claims (81.9%). Short-term disability claims increased following recall 
(4.0% vs. 4.4%, p< 0.01), with an average cost per claim of $10,849. CONCLUSIONS: 
Recall following traditional mammography represents a significant cost burden to 
employers with nearly one-in-six female employees with a new screening mam-
mogram undergoing additional diagnostic imaging and associated procedures. 
Strategies to reduce the burden of recall should not ignore indirect employer 
costs.
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OBJECTIVES: Current cost studies describing people with epilepsy do not segment 
the populations by seizure type. This paper produces an economic model of people 
experiencing seizures, including individuals with epilepsy, broken into novel cat-
egories useful in assessing the potential effect of future interventions. METHODS: 
Three-year’s worth of administrative claims data from Milliman’s commercially-
insured research dataset (n= 16.8 million 2012) was grouped into benefit service 
cost categories. Individuals experiencing seizures were extracted whose coverage 
included prescription drugs and whose medical claims contained the following 
ICD9CM diagnosis codes: 345.00, 345.01, 345.10, 345.11, 345.2, 345.3, 345.40, 345.41, 
345.50, 345.51 and 780.33. Individuals were grouped into three novel categories: 
Motor Seizures (345.10, 345.11, 345.3, 345.40, and 345.41), Post Traumatic Seizures 
(780.33) and Non-Motor Seizures (345.00, 345.01, 345.2, 345.50, and 345.51). RESULTS: 
Individuals experiencing seizures represented 0.4% of the population and accounted 
for 1.8% of allowed claims dollars. The odds of being admitted to the hospital for 
the Motor and Non-Motor Seizure groups were 5.5 and 4 times higher, respectively, 
with a 2-day longer average length of stay and total allowed claims dollars were 
5 and 4.2 times higher, respectively, than the standard population. The odds of 
being admitted for the Post Traumatic group was 9 times higher with an average 
length of stay almost 4 days longer and total allowed claims dollars were 6 times 
higher than the standard population. Other cost and utilization measures produced 
similar results. CONCLUSIONS: Individuals experiencing seizures are expensive 
when compared to the standard population. The excess utilization is in manageable 
healthcare cost categories. By utilizing these novel groups, case managers may find 
new ways to manage patients with epilepsy, target interventions and measure the 
success of those interventions.
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OBJECTIVES: In 2011, PhilHealth, the Philippine national health insurance provider, 
switched to a case rate scheme in tandem with a policy which prevents govern-
67 clinical records were analyzed. The average cost per CHKV children patient was 
US$517.5 (US$756.9 in equal or older than 1 year old, and US$375.1 in under one 
year population). The average length of stay was 2,7 days per patient. More prescript 
drugs were oral rehydration salts and acetaminophen. The more requested labs were 
hematic chart (13.8%) and protein C reactive (7.57%). CONCLUSIONS: Despite CHKV 
infection is not a lethal disease, it would cause a very huge impact in the health 
services and it associated cost in Colombia. Cost per case in children is high, and 
probably would be similar or higher in adult population.
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OBJECTIVES: To determine the direct cost of health care technologies used for treat-
ment of hypothyroidism in Ukraine. METHODS: We made the retrospective analysis 
of 81 patients’s medical records with hypothyroidism that were hospitalized to 
the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The 
method of pharmacoeconomic analysis “cost of illness” was used to estimate the 
cost of health care for patients with hypothyroidism. We have made calculations 
of costs: the cost of laboratory analysis, the cost of instrumental analysis, the cost 
of drug treatment, doctor’s consultations, costs of patient’s stay in hospital. While 
determining the direct costs of medical services in monetary terms we used the 
rates for medical services that were in Ternopil University Hospital. RESULTS: The 
study found that among the patients there were 23 (28.4%) men and 58 (71.6%) 
women aged 19 to 77 years (46.86±10.03). All patients have got to the hospital in 
stage of medication subcompensation. The average duration of stay in hospital for 
patients was 10.77±1.95 days. The total cost of laboratory tests was USD 4,231.95. The 
costs of instrumental methods of patients examination amounted USD 576.90. The 
cost of consultations by specialists was USD 769.36. In determining the amount of 
direct costs for medicines we found that the cost of drug treatment of the underlying 
disease was USD 52.40, the cost of drug therapy of hypothyroidism complications 
was USD 3,932.21. Total cost of patients stay in hospital was USD 9,411.80. After cal-
culation of all direct costs we determined that the total cost of hypothyroidism per 
patient is USD 234.26 per course of treatment. CONCLUSIONS: In the cost structure 
of health care provision for patients with hypothyroidism the most significant costs 
were spent for laboratory tests and for patient’s stay in hospital. The presence of 
underlying disease complications significantly increases cost of drugs.
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OBJECTIVES: To evaluate the clinical and economic impact of the incorporation of 
the monovalent conjugate vaccine against meningitis C caused by the Neisseria 
meningitides bacterium in children aged 0-4 years in the Brazilian public health 
system. METHODS: The analysis was developed for the period of 2009 to 2013. Were 
considered the actual number of cases of the disease recorded in the Notification 
Information System and deaths from meningitis C obtained from the Mortality 
Information System, and the estimates of long-term sequelae (amputation, skin 
scarring, renal failure, neurological sequelae and deafness) and of the costs due 
to sequelae, disease and vaccination. RESULTS: From 2009 to 2013, a decrease in 
the quantity of cases (684, 651, 563, 399 and 300, respectively) and in the number of 
deaths due to meningococcal meningitis (134, 111, 68, 61 and 47, respectively) was 
observed. There was also a reduction in the costs related with disease manage-
ment (R$ 1,572,632.28, R$ 1,496,759.67, R$ 1,294,432.71 and, R$ 917,368.83, respec-
tively) and with meningococcal meningitis sequelae (R$ 342,551.14, R$ 336,322.94, 
R$ 308,296.02, R$ 210,513.24 and, R$ 157,573.52, respectively). The three doses of 
the vaccine for children in their first year of life cost to the public treasury (R$ 
0.00, R$ 270,863,108.24, R$ 266,933,428.24, R$ 263,150,498.68 and, R$ 259,515,275.33, 
respectively). Therefore, the estimate of the value spent by the government in 
the evaluated years was R$ 1,915,183.42, R$ 272,696,190.85, R$ 268,536,156.97, R$ 
264,278,380.76 and, R$ 260,362,599.85. CONCLUSIONS: The Vaccine against menin-
gococcal meningitis type C implementation in SUS (Unique Health System - Sistema 
Único de Saúde in Portuguese) – the national public health system in Brazil – in 
infants in their first year of life generated reduction of incidence, mortality and 
sequelae due to the disease, decreasing, over the years, the cost due to the disease 
and to its sequelae, although adding the cost with vaccination.
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OBJECTIVES: To describe the prevalence of patient recall in the six months following 
traditional screening mammography and the related costs to Medicaid by patient 
race. METHODS: The Truven Health MarketScan Medicaid Multi-State Database was 
used to identify women aged 40-75 years undergoing screening mammography 
(index event) in 2010-2012. Women were required to have 12 months pre- and 6 
months post-index continuous enrollment and were excluded if they had mam-
mography or a breast cancer diagnosis in the 12 month pre-index period. Recall 
was defined as receipt of diagnostic mammogram or ultrasound in the six months 
following the index screen; patients with a subsequent breast cancer diagnosis were 
excluded from recall counts or costs. Payer cost per recall (2013 US$) was the sum 
of breast-related imagining and diagnostic procedures in the 6 months post-index, 
excluding patient payments and breast cancer treatment costs. RESULTS: A total of 
20,838 women undergoing a new screening mammogram met the study selection 
